tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemophilia A D006467 10 associated lipids
Hemorrhage D006470 15 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Hepatitis C D006526 7 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hernia, Ventral D006555 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Herpesviridae Infections D006566 4 associated lipids
HIV Seropositivity D006679 15 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hydronephrosis D006869 4 associated lipids
Hyperalgesia D006930 42 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hyperglycemia D006943 21 associated lipids
Hyperkalemia D006947 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Epperla N et al. Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. 2017 Transfusion pmid:28836275
Wiebe C et al. Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. 2017 J. Am. Soc. Nephrol. pmid:28729289
Das B et al. Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients. 2017 Pediatr Transplant pmid:27862703
Abongwa C et al. Successful treatment of tacrolimus-related pure red cell aplasia and autoimmune hemolytic anemia with rituximab in a pediatric cardiac transplant patient. 2017 Pediatr Blood Cancer pmid:28598573
Tamashiro EY et al. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients. 2017 Drug Metab Pers Ther pmid:28593920
Nakagawa K et al. Immunosuppressive treatment using tacrolimus promotes pregnancy outcome in infertile women with repeated implantation failures. 2017 Am. J. Reprod. Immunol. pmid:28466977
Ramirez R et al. Posterior Reversible Encephalopathy Syndrome After Orthotopic Heart Transplantation: A Case Report. 2017 Am J Case Rep pmid:28465499
Zheng X et al. Effect of FK-506 (tacrolimus) therapy on bone healing of titanium implants: a histometric and biomechanical study in mice. 2017 Eur. J. Oral Sci. pmid:27935130
Song K et al. Engineering of the LysR family transcriptional regulator FkbR1 and its target gene to improve ascomycin production. 2017 Appl. Microbiol. Biotechnol. pmid:28349163
Wan T et al. Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities. 2017 Int J Nanomedicine pmid:28260894
Ferjani H et al. Beneficial effects of mycophenolate mofetil on cardiotoxicity induced by tacrolimus in wistar rats. 2017 Exp. Biol. Med. (Maywood) pmid:26582055
Solari S et al. Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. 2017 Aliment. Pharmacol. Ther. pmid:28261844
Tremblay S et al. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. 2017 Am. J. Transplant. pmid:27340950
Vanhove T et al. Response to: 'Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'. 2017 Br J Clin Pharmacol pmid:28168728
Qin HZ et al. Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients. 2017 BMC Nephrol pmid:28056860
Dong Y et al. Risk Factors, Clinical Features, and Treatment Outcomes of Recurrent Mooren Ulcers in China. 2017 Cornea pmid:28060068
Dutta D et al. Recruitment of calcineurin to the TCR positively regulates T cell activation. 2017 Nat. Immunol. pmid:27941787
Naicker D et al. Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients. 2017 Pediatr. Nephrol. pmid:28660366
Kannegieter NM et al. Pharmacodynamic Monitoring of Tacrolimus-Based Immunosuppression in CD14+ Monocytes After Kidney Transplantation. 2017 Ther Drug Monit pmid:28640063
Gatault P et al. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. 2017 Am. J. Transplant. pmid:27862923